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Red blood cell-derived semaphorin 7A promotes
thrombo-inflammation in myocardial ischemia-
reperfusion injury through platelet GPIb
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Bernhard Nieswandt2 & Peter Rosenberger1✉
Myocardial ischemia is one of the leading health problems worldwide. Therapy consists of the
restitution of coronary perfusion which is followed by myocardial inflammation.
Platelet–neutrophil interaction is a crucial process during inflammation, yet its consequences
are not fully understood. Here, we show that platelet–neutrophil complexes (PNCs) are
increased in patients with acute myocardial infarction and that this is associated with
increased levels of neuronal guidance protein semaphorin 7A (SEMA7A). To investigate this
further, we injected WT animals with Sema7a and found increased infarct size with increased
numbers of PNCs. Experiments in genetically modified animals identify Sema7a on red blood
cells to be crucial for this condition. Further studies revealed that Sema7a interacts with the
platelet receptor glycoprotein Ib (GPIb). Treatment with anti-Sema7a antibody protected
from myocardial tissue injury. In summary, we show that Sema7a binds to platelet GPIb and
enhances platelet thrombo-inflammatory activity, aggravating post-ischemic myocardial tis-
sue injury.
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Myocardial infarction (MI) remains one of the leadinghealth disorders worldwide. In the treatment of MI,early reperfusion of the myocardium is the most
effective therapy to improve clinical outcome1. However, reper-
fusion of the previously ischemic myocardium may also induce
injury to the tissue2. This phenomenon, termed reperfusion
injury (RI), reduces the beneficial effects of early reperfusion and
is characterized by the infiltration of immune cells, mainly neu-
trophils, into previously ischemic areas, where they contribute to
injury through tissue inflammation3–6. Platelets are increasingly
recognized as central orchestrators of inflammatory processes,
mainly by enhancing immune cell recruitment and modulation of
endothelial barrier function, a phenomenon referred to as
thrombo-inflammation7. In the course of myocardial IR (ische-
mia reperfusion), the formation of platelet–neutrophil complexes
(PNCs) aggravates inflammatory tissue injury and is thus a
marker for tissue inflammation8,9. Given the clinical significance
of a dysfunctional myocardium through reperfusion injury, a
better understanding of this process and how it is guided is
needed.
The platelet-specific membrane receptor complex glycoprotein
Ib-IX-V (GPIb-IX-V), with its ligand-binding subunit GPIb,
mediates initial platelet adhesion under conditions of high shear
by binding to von Willebrand factor (vWF) immobilized at sites
of endothelial damage or activation10. In addition, GPIb binds a
number of other ligands, including P-selectin11, Mac-112, and
coagulation factors XI and XII13,14, and mediates thrombo-
inflammatory processes in different organs and disease settings15,
but the exact mechanisms are not fully understood. The infil-
tration of neutrophils into inflammatory tissue sites is influenced
by neuronal guidance proteins (NGPs), a class of guidance cues
that was originally identified in the developing human nervous
system16. Among them is the family of semaphorins including
semaphorin 7A (SEMA7A for human, Sema7a for murine pro-
tein), which plays key roles in the regulation of the immune
response17. Sema7a was initially described in the context of
axonal growth as a messenger protein involved in the guidance of
synapse formation for the neuronal circuitry18. Subsequent work
has shown that it enhances autoimmune encephalitis through T-
cell-dependent cytokine production and that it can also increase
the infiltration of neutrophils into sites of tissue hypoxia19,20. A
role for Sema7a in the cardiovascular system has been described
recently in atherogenesis21. Hu et al. showed that disturbed flow
resulted in an induction of Sema7a on vascular endothelium and
that this results in an increased expression of leukocyte adhesion
molecules on the endothelial surface. Sema7a is also expressed in
platelets, but its role in platelet function is unknown22. Given the
expression pattern of Sema7a within the cardiovascular system,
we hypothesized it might have a role in myocardial IR injury.
We report here that soluble SEMA7A is elevated in plasma of
patients with acute MI, and that Semaphorin 7A holds significant
impact on the extent of MIRI. We show that Sema7a promotes
myocardial thrombo-inflammation and tissue damage by rein-
forcing platelet thrombotic activity and PNC formation through a
platelet GPIb-dependent mechanism. Conversely, inhibition of
Sema7a results in reduced myocardial IR injury and can be
pursued as future strategy to reduce post-ischemic tissue damage.
Results
Patients with MIRI show increased PNCs and plasma
SEMA7A. The number of PNCs increases in myocardial tissue
during MIRI9. The detrimental effects of PNCs have been
demonstrated in other organs, such as the lung, where they
increase inflammatory tissue damage, resulting in impaired organ
function8. In an attempt to better understand the interaction of
platelets and neutrophils and the formation of PNCs during
inflammatory myocardial injury, we obtained blood samples from
patients with active myocardial ischemia and tested them for the
presence of PNCs by FACS analysis. We compared these samples
to patients undergoing cardiac surgical operations, who are also
exposed to reperfusion after extracorporal circulation (HLM).
These patients did not show signs of active ischemia. In addition,
we obtained blood from off-pump cardiac surgical operations
without reperfusion injury as well as healthy controls. We found
that the patients suffering from an acute MI showed significantly
more CD42b-positive neutrophils (i.e., PNCs) compared to
healthy controls and patients undergoing cardiac surgical pro-
cedures with or without extracorporal circulation. Notably, the
platelets in the conjugates were fully activated, as shown by the
marked integrin αIIbβ3 activation (PAC-1 binding) and CD62P
exposure (Fig. 1a–d). Given that reperfusion of ischemic tissue
triggers inflammation and our previous finding that SEMA7A
holds significant pro-inflammatory capacity, we also measured
soluble SEMA7A in the blood of these patients. Indeed, SEMA7A
increased in the plasma of MI patients but not in any of the other
tested patient groups (Fig. 1e, Supplementary Table 1). We also
found that the SEMA7A expression on erythrocytes is not age
dependent (Supplementary Fig. 1). Experiments in mice revealed
that plasma Sema7a increased very rapidly during cardiac
ischemia, with a significant elevation detected as early as after 1
min of reperfusion (Supplementary Fig. 2). SEMA7A was released
from erythrocytes in response to shear stress or tissue hypoxia,
both of which are present during myocardial ischemia reperfu-
sion in the affected areas (Supplementary Fig. 3).
Injection of Sema7a aggravates myocardial IR injury. The
profound increase in Sema7a in plasma of patients and mice with
myocardial ischemia raised the possibility that it has a functional
role in the progression of myocardial IR injury. To test this
directly, we injected recombinant Sema7a (rmSema7a fusion
protein, 1 µg/mouse prior to experiment) into WT animals and
found that this resulted in markedly increased infarct size com-
pared to appropriate IgG Fc control (rmIgG2A Fc)-injected ani-
mals (Fig. 2a, b). This finding correlated with increased troponin
I, a marker of myocardial tissue damage. Histological sections
revealed increased tissue injury in Sema7a-injected animals
compared to Fc controls and a reduced number of PNCs in the
tissue areas at risk (Fig. 2c, d). In cell culture experiments, we
found no direct pro-apoptotic effect of human Sema7a (rhSE-
MA7A) on cardiomyocytes, as assessed by the activation of cas-
pase 3 (Supplementary Fig. 4a, b). After observing more PNCs
within the myocardial tissue, and knowing the detrimental effects
these PNCs can have8,9, we next used flow cytometry to test for
the presence of PNCs in whole blood (gating strategy Supple-
mentary Fig. 5a). We found markedly increased numbers of
PNCs in the blood of mice injected with rmSema7a, and the
conjugates (Fig. 2h) also displayed stronger signals for the platelet
markers GPIb, CD62P, and activated integrin αIIbβ3 (JON/A)
(Fig. 2e–g, Supplementary Fig. 7a, b). To test whether this would
be reflected by PNCs infiltrating the area at risk (AAR), we
extracted this area and determined the number of PNCs within
the myocardial tissues for further analysis with flow cytometry
(gating strategy Supplementary Fig. 5b). We found that more
PNCs had extravasated into the myocardium in the AAR in the
animals injected with rmSema7a and that the conjugates dis-
played significantly increased signals for GPIb, P-selectin, and
activated integrin αIIbβ3 (JON/A) on neutrophils (Fig. 2i–l,
Supplementary Fig. 7c, d). We also tested the influence of
rmSema7a on the rolling of neutrophils and found that rmSe-
ma7a influenced the adhesion of neutrophils in vitro and in vivo
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(Supplementary Fig. 6 and Supplementary Video 1). This is
consistent with our previous findings that Sema7a expressed on
the surface of endothelial cells increases the transmigration of
neutrophils into inflamed tissues19.
Markedly reduced myocardial IR injury in Sema7a−/−mice. To
further investigate the role of Sema7a in myocardial IR injury, we
employed Sema7a−/− animals and their littermate controls. Since
Sema7a is involved in fibrotic transformation of tissues23, we first
assessed cardiac function in untreated WT and Sema7a−/− ani-
mals by dynamic magnet resonance tomography. We did not
detect differences in the anatomy or cardiac performance para-
meters of Sema7a−/− mice versus littermate controls (Fig. 3a, b,
Supplementary Fig. 8). Next, we exposed the Sema7a−/− mice to
MIR and found that they developed dramatically smaller infarcts
and displayed decreased plasma troponin I compared to litter-
mate controls (Fig. 3c, d). Histological sections revealed decreased
tissue injury in Sema7a−/− animals compared to littermate
controls and a reduced number of PNCs in the tissue areas at risk
(Fig. 3e, f). Flow-cytometric analysis revealed decreased numbers
of PNCs (Fig. 3j) in the blood of Sema7a−/− animals compared to
controls, and the conjugates displayed lower levels of platelet
activation markers (surface P-Selectin and activated integrin
αIIbβ3 (JON/A)) in the early phase after IR (Fig. 3g–i, Supple-
mentary Fig. 9a, b). We again tested whether this would be
reflected within the PNCs in the AAR. We extracted this area and
counted the PNCs within the myocardial tissues. Using flow
cytometry, we found reduced number of PNCs within the AAR
and the conjugates displayed decreased signals for GPIb, activated
integrin αIIbβ3 and P-Selectin on neutrophils in the AAR of
Sema7a−/− animals (Fig. 3k–n, Supplementary Fig. 9c, d).
Red blood cell-derived semaphorin 7a is central to MIRI. Next,
we sought to identify the cellular source of soluble Sema7a that
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Fig. 1 Patients with acute myocardial infarction show increased PNCs and plasma SEMA7A. Samples were taken from patients with acute myocardial
infarction, patients undergoing cardiac surgical operations with (HLM) or without cardiopulmonary bypass (Off-Pump) and healthy controls. a Flow-
cytometric evaluation of PNCs’ expression of GPIb (CD42b) in the presented patient groups (Healthy, MI, and HLM n= 7; Off-pump n= 8). b Flow-
cytometric evaluation of PNCs for CD62P expression on neutrophils (n= 4;5;5;5). c PAC-1 binding to PNCs (n= 4;8;7;6). d Representative flow-cytometric
histograms of groups measured and e Sema7a in the plasma of patients with acute MI (n= 10), patients undergoing cardiac surgical operations with
(HLM) or without cardiopulmonary bypass (Off-Pump) and healthy controls (all n= 4/group). For comparison we performed one-way analyzes of variance
followed by Dunnett’s tests to group myocardial infarction. Data are mean ± SD; *p < 0.05, **p < 0.01, and ***p < 0.001 as indicated.
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mediated the observed pathogenic effect. Sema7a is expressed in
several organs and tissues, with high abundance on red blood cells
(RBCs) and only low expression within the myocardial tissue
(Supplementary Fig. 10a–c). Therefore, we generated animals with
genetic deletion of Sema7a in endothelial cells (Sema7aloxP/loxP
Tie2Cre+), cardiomyocytes (Sema7aloxP/loxPMyh6Cre+), RBCs
(Sema7aloxP/loxPHbbCre+), and immune-competent cells
(Sema7aloxP/loxPLysMCre+) and subjected them to the MIRI
model. In the Sema7aloxP/loxPHbbCre+ animals, we found a sig-
nificant reduction in infarct size, correlating well with reduced
plasma TnI (Fig. 4a, b). Immunohistological analysis revealed a
reduced number of PNCs within the myocardial tissue of these
animals compared to WT control (Fig. 4c, d). Injection of rmSe-
ma7a showed that these results could be reversed in the
Sema7aloxP/loxPHbbCre+ animals although injection of Sema7a
resulted in higher troponin levels in these animals (Supplementary
Fig. 11a–d). In the Sema7aloxP/loxPMyh6Cre+ animals, we did not
find a significant alteration of myocardial IR injury (Fig. 4e, f) and
no changes compared to littermate controls when looking at the
PNCs in the myocardial tissue (Fig. 4g, h). When exposing the
Sema7aloxP/loxPTie2Cre+ animals to the same model, we found
significantly smaller infarcts compared to controls (Fig. 4i, j). This
protection was also reflected by a reduced number of PNCs,
whereas the reduction in troponin I did not reach statistical sig-
nificance (Fig. 4k, l). In contrast, infarct size was unaltered in
Sema7aloxP/loxPLysMCre+mice compared to controls (Fig. 4m, n),
as was troponin I level (Fig. 4o) and number of PNCs in the
myocardial tissue (Fig. 4p). This approach showed that Sema7a
expression on RBCs is critical to induce PNC formation and
myocardial tissue injury.
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Fig. 2 Injection of Sema7a results in increased MIRI and PNC formation. Mice were injected with either recombinant semaphorin 7a (rmSema7a) or Fc
control (rmIgG2A Fc) and then subjected to 1 h of ischemia followed by 2 h reperfusion. Samples were taken after 1 or 120min reperfusion. a Representative
TTC-stained slices of myocardial tissue showing infarcted area (blue/dark= retrograde Evans blue staining; red and white=AAR, white= infarcted tissue;
120min) with b systematic evaluation of infarct sizes and corresponding troponin I plasma levels (120min, n= 6/group). c Representative histological
sections (scale bar 100 µm) of WT animals injected with either IgG Fc control or rmSema7a (120min) and d number of PNCs counted in myocardial tissue
sections of AAR in animals (120min, n= 9/group). e Representative flow-cytometric plots of PNCs in the blood of sham animals, rmSema7a- or IgG Fc
control–treated mice, showing GPIb (CD42b) and P-selectin (CD62P) after 1 and 120min reperfusion. Systematic evaluation of flow-cytometric expression
of mean fluorescence intensity (MFI) for f GPIb (CD42b, n= 6;6;4;4;6) and g P-selectin (CD62P, n= 6;3;5;3;7) expression. h Systematic evaluation of
PNCs in % by flow cytometry in the blood of animals injected with rmSema7a or Fc control at 1 and 120min (n= 6;4;4;4;5). i Representative flow-
cytometric plots of PNCs in the AAR showing the presence of GPIb (CD42b) and P-selectin (CD62P) after 1 and 120min reperfusion. Systematic
evaluation of flow-cytometric expression of MFI for j GPIb (CD42b, n= 5;5;5;4;6) and k P-selectin (CD62P, n= 6;4;5;3;5) and l systematic evaluation of
PNCs in % by flow cytometry in the AAR of animals injected with rmSema7a or Fc control at 1 and 120min (n= 5;4;5;5;5). Comparisons in b and d were
analyzed by unpaired two-tailed Student’s t-tests (data are mean ± SD). For f–h, j–l we used log transformation of data to conform normality. For log-
transformed data, unpaired two-tailed Student’s t-tests were performed on the log values and results are displayed as geometric means and their 95%
confidence intervals. *p < 0.05, **p < 0.01, and ***p < 0.001 as indicated.
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Sema7a interacts with platelet glycoprotein Ib. The above
experiments have shown that Sema7a enhances platelet activation
and PNC formation in the setting of myocardial IR. To test
whether Sema7a directly acts on platelets, we first assessed its
effects on platelet function in standard aggregometry. Unex-
pectedly, Sema7a did not induce any detectable platelet activation
or aggregation at the concentration of 1 µg/ml. This was also
confirmed by flow-cytometric analysis of platelet activation.
Increasing concentrations of Sema7a had no effect on integrin
αIIbβ3 activation (JON/A-PE) or P-selectin exposure under static
conditions. In sharp contrast, a profound prothrombotic activity
of Sema7a was observed when thrombus formation on collagen
was assessed under flow using a whole-blood perfusion system. At
a medium to high shear rate (1000 s−1), reflecting arterial blood
flow, Sema7a markedly increased both surface area covered by
platelets and thrombus volume (Fig. 5a, b), and the same effect
was observed at a low shear rate (400 s−1, Supplementary
Fig. 12a, b). The flow-dependence of the prothrombotic Sema7a
effect indicated a possible involvement of the vWF receptor,
GPIb-IX, in this process, which is particularly important for
thrombus formation under conditions of high shear24. To test this
directly, we inhibited GPIb-IX by adding Fab fragments of the
antibody p0p/B, which completely blocks the ligand-binding site
on the GPIbα subunit of the receptor complex15. Under these
conditions, the thrombus-promoting effect of Sema7a was lost
completely at both low and high shear rates, demonstrating that it
was GPIb-dependent (Fig. 5a, b). This result was further con-
firmed in mice in which the ectodomain of GPIbα was replaced
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by the human IL-4 receptor (GPIb-IL-4tg) (Fig. 5c, d), where
Sema7a did not induce an increase in surface coverage or
thrombus volume in the whole-blood perfusion system.
To test whether the thrombo-inflammatory action of Sema7a
myocardial IR injury also depends on platelet GPIb, we first
subjected GPIb-IL-4tg animals to the MIRI model. Strikingly,
these animals showed markedly reduced infarct size compared to
WT controls, which was also reflected in the troponin I
measurements. Furthermore, treatment of these mutant animals
with Sema7a did not enhance MIRI, showing that this pathogenic
activity of Sema7a was entirely GPIb dependent (Fig. 5e, f). When
evaluating the tissue sections of the AAR of these animals, we
found a low number of PNCs within myocardial tissue sections
(Fig. 5g, h). To test a possible interaction of Sema7a with GPIb,
we performed coimmunoprecipitation experiments. In a first step,
we immunoprecipitated Sema7a from blood and myocardial
tissue samples and blotted for the presence of GPIb. Indeed, GPIb
coimmunoprecipitated with Sema7a in blood and especially the
myocardial AAR in response to MIR. We then reversed this
approach with immunoprecipitation of GPIb and blotting for
Sema7a. Again we detected an interaction of Sema7a with GPIb
in blood and AAR in response to MIR (Fig. 5i, j).
Anti-Sema7a reduces PNC formation and MIRI. To test whe-
ther inhibition of endogenous Sema7a affects MIRI, we injected a
function-blocking anti-Sema7a antibody or IgG control (1 µg/
mouse) before the start of reperfusion. Indeed, anti-Sema7a
treatment resulted in decreased infarct size and reduced troponin
I compared to IgG control-injected animals (Fig. 6a, b). The
histological sections of the AAR revealed decreased tissue injury
in the anti-Sema7a-injected animals compared to IgG controls,
with a reduced number of PNCs in the tissue areas at risk (Fig. 6c,
d). Flow cytometry showed an increased number of CD42b-
positive and P-selectin-positive neutrophils in the blood of the
IgG-injected animals early on in the process after IR that was not
observed in the anti-Sema7a-injected animals (Fig. 6e–g, Sup-
plementary Fig. 13a, b). Further, we found a significantly reduced
number of PNCs in the blood of these anti-Sema7a-injected
animals (Fig. 6h). Analysis of the AAR revealed a marked increase
in PNCs with fully activated platelets (evident by high signals for
GPIb, activated integrin αIIbβ3 and P-selectin) at the later time
point (120 min) in the IgG control-injected animals, which was
virtually absent in anti-Sema7a-injected animals (Fig. 6i–k, Sup-
plementary Fig. 13c, d), and a lower number of PNCs within the
AAR (Fig. 6l). These data demonstrate that PNC formation has
detrimental effects on myocardial tissue injury in experimental
myocardial IR and can be effectively prevented by inhibition of
endogenous Sema7a.
Discussion
Myocardial ischemia followed by reperfusion remains one of the
most significant health problems worldwide. Intervention to
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recanalize the occluded coronary artery is a crucial part of the
initial therapy for this condition and significantly improves
overall patient outcome1. Following occlusion, the subsequent
reperfusion injury of the myocardium is the result of an
inflammatory response that affects a large portion of patients
with MI and can then result in severe myocardial dysfunction.
Here, we show that the neuronal guidance protein semaphorin
7a released from the membrane of red blood cells is a mediator
of inflammatory myocardial injury. We further provide evidence
that Sema7a interacts with platelet GPIb and thereby
promotes the formation of platelet–neutrophil complexes and
their translocation into the affected myocardium, thereby
increasing myocardial injury. To illustrate the role of Sema7a on
platelets and the effect of Sema7a on MIRI we have provided a
sketch in Fig. 7. Our results indicate that a strategy to interfere
with the Sema7a–GPIb interaction might result in reduced
cardiac damage and improved myocardial outcome following
MI and should therefore be pursued as a therapeutic option in
the future.
GPIb-IX-V is a multifunctional and platelet-specific receptor
complex with essential functions in the biogenesis, hemostatic
functions and clearance of platelets. In addition, it is increasingly
recognized that GPIbα is a key orchestrator of platelet–immune
cell interactions and thrombo-inflammatory processes, such as
experimentally induced IR injury in brain and liver in mice,
which make the protein a promising therapeutic target. However,
the mechanisms underlying these multiple functions of the GPIb-
IX-V complex are largely elusive, mainly for two reasons. On the
one hand, the intracellular signaling pathways and resultant cel-
lular responses downstream of GPIbα have been difficult to study
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and are largely unknown. On the other hand, GPIbα binds a large
number of immobilized as well as soluble ligands12–14,24, and it is
not clear how they may differentially trigger specific platelet
functions. We established soluble Sema7a as an interaction
partner of GPIbα that promotes both the thrombotic as well as
the thrombo-inflammatory activity of the cells. We could not
identify the underlying signaling pathways downstream of GPIb-
IX-V, but it appears that the presence of shear flow is required for
this pathway to be initiated, indicating that the mechanosensing
activity of the receptor may be modulated by Sema7a binding.
Inhibition of the ligand-binding domain of GPIbα has been
identified as a potential therapeutic strategy to interfere with
acute thrombotic disease states as well as the thrombo-
inflammatory sequelae in ischemic brain infarction15. In a
recent study, we further demonstrated that GPIbα inhibition by
injection of Fab fragments of the function-blocking antibody p0p/
B profoundly reduced immune cell infiltration in a myocardial IR
model but did not significantly reduce infarct size. Of note, in that
study the treatment was administered after initiation of
reperfusion to avoid excessive surgery-related bleeding25. In the
current study, we used a different surgical protocol and did not
use the same p0p/B antibody approach to interfere with platelet
activity during reperfusion. Instead, we used animals lacking a
functional GPIb receptor through genetic deletion and found
markedly reduced MIRI, and this was not altered by the injection
of Sema7a. In vitro, Sema7a strongly enhanced thrombus for-
mation under flow, and this effect was completely reversed by
GPIb inhibition. This strongly suggests that Sema7a mediates its
action through GPIb, and our immunoprecipitation experiments
indicated a direct interaction of the two molecules in blood and
myocardial tissue following MIR. Certainly, to some extent
Sema7a also exerts its effect through the activation of neutrophils.
Yet given the data of the tissue-specific deletion of Sema7a and
the experiments in GPIb-IL-4tg animals the predominant role of
Sema7a during reperfusion injury is mediated by the effect
Sema7a on platelets19. Further studies will be required to char-
acterize the interaction in more detail and to understand how it
exerts its pro-thrombo-inflammatory effects.
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Fig. 6 Anti-Sema7a reduces MIRI, platelet activation and PNC formation. Animals were injected with either anti-semaphorin 7A antibody (anti-Sema7a)
or IgG control 5 min before starting 120min reperfusion after 60min of ischemia, with samples taken after 1 or 120min of reperfusion. a Representative
TTC-stained heart slices of myocardial infarcts (blue/dark= retrograde Evans blue staining; red and white=AAR, white= infarcted tissue) with
b systematic evaluation of infarct sizes (n= 6/group) and correlating troponin I plasma levels (n= 6;8). c Representative histology sections (scale bar
100 µm) of WT animals injected with either IgG control or anti-Sema7a and d number of PNCs counted from myocardial tissue sections (n= 9/group).
e Representative flow cytometry plots of PNCs in the blood of Sham, anti-Sema7a-injected or IgG control-injected animals, expressing GPIb (CD42b) and
P-selectin (CD62P). Systematic evaluation of flow-cytometric expression of mean fluorescence intensity (MFI) for f GPIb (CD42b, n= 5;4;3;4;5) and
g P-selectin (CD62P, n= 6;4;4;3;5) and h systematic evaluation of PNCs in % by flow cytometry in the blood of animals injected with anti-Sema7a or IgG
control at 1 and 120min (n= 3;4;4;3;4). i Systematic evaluation of flow-cytometric expression of MFI for j GPIb (CD42b n= 4;5;3;3;4) k P-selectin
(CD62P, n= 4/group) and l systematic evaluation of PNCs in % by flow cytometry in the AAR of animals injected with anti-Sema7a or IgG control at 1 and
120min (n= 5;6;5;4;4). Comparisons in b, d were analyzed by unpaired two-tailed Student’s t-tests (data are mean ± SD). For f–l we used log
transformation of data to conform normality. For log-transformed data, unpaired two-tailed Student’s t-tests were performed on the log values and results
are displayed as geometric means and their 95% confidence intervals. *p < 0.05, **p < 0.01, and ***p < 0.001 as indicated.
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Sema7a is expressed in several tissues in humans and mice and
is rapidly released from the cell membrane during hypoxia.
Sema7a stimulates cytoskeletal reorganization in melanocytes and
monocytes, which translates into cell morphology changes that
can result in the spreading and migration of these cell
types18,26,27. Sema7a can enhance inflammation in the course of
lung injury and tissue hypoxia through action on endothelial cells
and T cell-dependent cytokine production19,20,28. Here, we have
demonstrated that RBC-derived Sema7a is crucial for the
described thrombo-inflammatory platelet activity in the setting of
experimental MIRI. Sema7a is expressed on human RBCs and is
known as the John Milton Hagen blood group antigen; it is
released from the cells very rapidly and is present as free Sema7a
within plasma29. RBCs influence hemostasis and pathological
conditions by several known mechanisms: through the supply of
ADP, ATP, and nitric oxide30,31. Whether Sema7a holds a direct
impact on erythrocytes is not described to date. More recent data
have shown that RBCs can contribute to the generation of
thrombin32. However, little is known about a direct influence of
RBCs on platelet function. A recent study by Klatt et al. proposed
that RBCs contribute to thrombus formation by the FasL/FasR
(CD95)-dependent interaction with platelets33. There is no
evidence that the Sema7a effect reported here is linked to this
process or interacts with it. Our data rather show that
Sema7a released from RBCs promotes thrombus formation and
thrombo-inflammatory myocardial injury through its interaction
with GPIb.
Currently, there is no specific treatment available that targets
this thrombo-inflammatory myocardial reperfusion injury.
Myocardial cell death during this phase is mediated by a com-
bination of excess inflammation, the presence of thrombi in the
coronary microcirculation, metabolic modulation, and electrolyte
imbalances. The infiltration of inflammatory cells into the pre-
viously ischemic myocardium is a key component of this process,
and the interaction of platelets with neutrophils during this phase
enhances the inflammatory reaction. We and others have pre-
viously shown that the formation of PNCs aggravates inflam-
matory tissue injury, especially during myocardial reperfusion8,9.
The infiltration of these inflammatory cells and PNCs into the MI
zone leads to elevated concentrations of reactive oxygen species,
cytokine release, and the activation of apoptotic and necrotic cell
death pathways. This process occurs rapidly, within minutes after
the initiation of reperfusion. The expression of adhesion mole-
cules, which act as chemoattractants for neutrophils, and the
complement cascade are activated during this phase. In addition,
activated platelets release adhesion proteins, growth factors,
chemokines, interleukins, and coagulation factors into the local
environment. This further alters the chemotactic, adhesive, and
proteolytic properties of endothelial cells and promotes the che-
motaxis of inflammatory cells to the site of inflammation. We
show here that Sema7a strongly increases the formation of PNCs,
which are then translocated into the myocardium, where they
enhance the above-described effects. Inhibition of Sema7a action
through the injection of anti-Sema7a antibody significantly
ameliorated this process and resulted in reduced myocardial cell
death. We also showed that Sema7a did not directly induce cell
death in cardiac myocytes, since this would likely involve caspase-
3 activation, which we did not see following exposure of human
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Fig. 7 Schematic drawing of the role of Sema7a during myocardial IR. a During myocardial ischemia shear stress and hypoxia result in cleavage of
Sema7a from the surface of erythrocytes as the main source of Sema7a within the vascular bed. b The released Sema7a then engages the Glycoprotein Ib
receptor and activates platelets which then exposes the integrin receptors resulting in platelet–neutrophil complex formation (PNCs). c Activated platelets
and PNCs migrate from the vasculature to the ischemic tissue which results in tissue injury and destruction.
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myocytes to Sema7a. Our results strongly point to the action of
Sema7a on platelets, its interaction with GPIb, formation of PNCs
and increased inflammatory tissue injury in the myocardium
through this process.
In summary, Sema7a has a significant impact on myocardial
ischemia/reperfusion injury. Although Sema7a has no direct
action on myocardial cell death, erythrocyte-derived Semaphorin
7A markedly promotes PNC formation and thrombo-
inflammation through platelet GPIb. This process enhances
myocardial cell death through activated inflammation. Inter-
ference with the Sema7a–GPIb axis could be a potent strategy to
inhibit this process and significantly reduce myocardial IR injury.
Methods
Ethic statement. Animal protocols were in accordance with the German guide-
lines for use of living animals and were compliant with all ethical regulations and
approved by the Institutional Animal Care and the Regierungspräsidium Tübingen
and Würzburg, and the Landesamt für Verbraucherschutz Niedersachsen.
Approval for human sample processing was obtained by the ethics committee of
the University of Tübingen (Institutional Review Board). Samples of patients with
MI were obtained at presentation to the catheter laboratory and processed
(Biobank: 266/2018BO1; Sema7a subanalysis: 266/2018BO2; Clinicaltrial.gov:
NCT01417884). Patient samples before and after cardiac surgery were collected as
part of the TüSep-Study (NCT02692118). Written informed consent was obtained
from each patient before samples were taken. All ethical regulations were
complied with.
Processing of human blood samples. Human blood samples were taken during
coronary intervention, at the end of cardiopulmonary bypass or during occlusion
of the coronary arteries during off pump cardiac surgery and processed for flow
cytometry. In addition, blood was centrifuged to obtain plasma samples, which
were then stored and measured. In another set of experiments, human whole blood
withdrawal from healthy donors (Ethics approval 507/2017BO1) was focused on
erythrocytes population by flow cytometry and SEMA7A expression was assessed
with 1:500 incubation with anti-human SEMA7A monoclonal antibody conjugated
with Allophycocyanin (R&D Systems #FAB20681A Minneapolis, USA).
Mice. Sema7a−/− mice were generated, validated, and characterized18. The
corresponding WT controls were bred as littermates of the Sema7a−/− mice. In a
subset of experiments, a newly generated Sema7a floxed mouse line (Sema7aloxP/loxP/
Ozgene) on a C57BL/6 background was crossbred with the following Cre
recombinase-positive mouse lines to obtain tissue-specific gene deletion: erythrocyte-
specific HbbCre+, myocardial cell-specific Myh6Cre+; endothelial cell-specific
Tie2Cre+; and immune cell-specific LysMCre+. In the experiments, tissue-specific
gene deleted Sema7a mouse lines (Sema7aloxP/loxPHbbCre+; Sema7aloxP/loxP
Myh6Cre+, Sema7aloxP/loxPTie2Cre+; and Sema7aloxP/loxPLysMCre+) were used.
Sema7aloxP/loxPCre-negative (−) littermates were used as controls. In a subset of
experiments, we used a functional GPIb-knockout mouse line (GPIb-IL4-tg) to test the
interference of Sema7a with the GPIb receptor34. In a subset of experiments
Sema7aloxP/loxPHbbCre+ animals were reconstituted with recombinant mouse
Sema7a (rmSema7a; R&D SYSTEMS, Minneapolis, USA) or recombinant mouse
IgG2A Fc (rmIgG2A Fc; control).
Murine myocardial ischemia and reperfusion model. This animal model is
described in detail elsewhere35. Subsets of animals received either recombinant
mouse Sema7a (rmSema7a) or recombinant mouse IgG2A Fc (rmIgG2A Fc; control)
before the start of experiments or Sema7a antibody (abcam ab23578, Cambridge,
UK; anti-Sema7a) or, as control, rabbit IgG sc-2027 (Santa Cruz Biotechnology,
Santa Cruz, USA) 5 min before the onset of reperfusion intravenously. For a
detailed description see Supplementary material.
Immunohistochemical techniques. For immunohistochemical staining, the Vec-
tastain ABC Kit (Linaris, Wertheim, Germany) was used. After inhibiting the
nonspecific-binding sites with avidin blocking solution (Vector), the sections were
incubated 1:900 anti-CD41 primary antibody (rabbit anti-mouse CD41, abcam
ab63983, Cambridge, UK) overnight at 4 °C. Tissue sections were then incubated
with biotinylated anti-rabbit IgG for 1 h followed by Vectastain ABC reagent for
30 min, then developed via DAB substrate. Later, PMN were stained with 1:1000
with a rat anti-mouse Ly6B.2 primary antibody (BioRad, MCA771GA, Basel,
Switzerland) and HistoGreen as substrate (Linaris, Wertheim, Germany). Coun-
terstaining was performed using nuclear fast red (Linaris, Wertheim, Germany).
Histological sections were analyzed for the presence of PNCs by manual count
within three independent tissue sections of each animal at magnification ×400.
Troponin I measurement. The troponin blood plasma levels of probes taken by
central venous puncture after 120 min of reperfusion was measured using the
ELISA Kit SEA478Mu (Cloud-Clone Corp., Houston, USA) for murine troponin I
type 3 (TNNI3).
Caspase 3 staining and Caspase 3 ELISA. Human cardiac myocytes (HCM-c,
primary cell line, order-number: C-12810; lot-number: 9083205.4, PromoCell,
Heidelberg, Germany) were grown to confluence on chamber slides followed by 6 h
of stimulation with rhSEMA7A, rhIgG1 Fc, BSA, or staurosporine (Sigma-Aldrich,
Munich, Germany), all 1 µg/ml. After fixation, cells were stained with 1:100 rabbit
polyclonal anti-caspase3 antibody (abcam #ab44976 Cambridge, UK). For a
detailed description see Supplementary material.
Sema7a ELISA. Sema7a ELISAs were performed according to the manufacturer’s
instructions using the ELISA Kit SEB448Hu for human and SEB448Mu for murine
Sema7a (Cloud-Clone Corp., Houston, USA).
RT-qPCR. For RNA extraction, we used the peqGOLD TriFast™ (Peqlab; Germany;
Erlangen) following the manufacturer’s instructions. The iScript kit from Bio-Rad
(Bio-Rad; Germany; Munich) was used for cDNA synthesis. Semiquantitative
analysis of murine Sema7a was performed by real-time PCR using the sense primer
5′-GTG GGT ATG GGC TGC TTT TT-3′ and the antisense primer 5′-CGT GTA
TTC GCT TGG TGA CAT-3′. The reference gene was the murine 18S rRNA gene,
with the following set of primers: sense 5′-GTA ACC CGT TGA ACC CCA TT-3′
and antisense primer 5′-CCA TCC AAT CGG TAG TAG CG-3′.
Protein analysis. Murine tissue was homogenized and resuspended in RIPA
buffer. Probes were separated in SDS–polyacrylamide gels and blotted on PVDF
membranes. The following antibodies were used in murine samples: 1:200 anti-
Sema7a antibody (abcam #ab23578, Cambridge, UK) and, for the control of
loading conditions, 1:300 GAPDH antibody (Santa Cruz Biotechnology #sc-25778,
Santa Cruz, USA). For human samples, we used 1:200 polyclonal goat anti-Sema7a
antibody (R&D Systems #AF2068, Minneapolis, USA) and 1:1000 β-Actin antibody
(Santa Cruz Biotechnology #sc-130656). Bands were detected through chemilu-
minescence reaction of HRP-conjugated antibodies and developed with Luminol
reagent (Santa Cruz Biotechnology #sc-2048).
Coimmunoprecipitation and immunoblotting. Coimmunoprecipitation (Co-IP)
was performed according to the manufacturer’s instructions using the Pierce Co-IP
Kit (cat. no. 261498, Thermo Fisher Scientific, Waltham, USA). Briefly, murine
samples were taken after 60-min ischemia followed by 1-min (blood) or 15-min
(heart tissue, AAR) reperfusion. Then, 250 µl citrate+ blood was lysed in 1 ml IP-
Lysis/wash buffer and kept on ice. AAR was incubated in 1 ml IP-Lysis/wash buffer
and homogenized in a Precellys 24 (VWR/Peqlab, Erlangen, Germany) and kept at
4 °C for 60 min. All samples were centrifuged at 13,000 × g for 10 min. Total
protein of lysates was measured by the Pierce™ BCA Protein Assay Kit (Thermo
Scientific, #23225) and analyzed in an Infinite® M200 Pro Plate Reader (Tecan,
Männedorf, Switzerland). Ten micrograms of mouse monoclonal antibody against
Sema7a (Santa Cruz Biotechnology #sc374432, Santa Cruz, USA) or 10 µg of non-
commercialized36 rat monoclonal antibody against GPIb (p0p4) were immobilized
on the Amino Link Plus Coupling Resin. As IgG control, 10 µg rat IgG (sc2016;
Santa Cruz Biotechnology) or mouse IgG (X0943; Dako, Glostrup, Denmark) was
used. For protein analysis, 30 µl per Co-IP eluate was applied to SDS–PAGE. For
immunodetection, a rabbit polyclonal antibody against Sema7a (sc135263; Santa
Cruz Biotechnology) and the non-commercialized37 monoclonal antibody (p0p5)
against GPIb were employed. Species-matched alkaline phosphatase-conjugated
secondary antibodies were used (Santa Cruz Biotechnology, goat anti rabbit-IgG-
AP; #sc-2007, and Thermo Fisher Scientific goat anti rat-IgG-AP; #A18868;).
Protein detection was performed using a BCIP/NBT substrate.
Cardiac magnetic resonance imaging (MRI). Animals were subjected to cardiac
MRI at 22 weeks of age. Analysis was performed on a clinical workstation with
semi-automated contour-tracing software (CVI42, Release 4.1.8 (201), Circle
Cardiovascular Imaging Inc., Calgary, Canada). For a detailed description see
Supplementary material.
Flow chamber experiments. Platelet adhesion under flow was measured by per-
fusion of murine whole blood on collagen-coated cover slips (200 µg/ml fibrillar
type I collagen) at 1000 or 400 s−1, as indicated. Platelets were labeled with
0.2 µg/ml of DyLight 488-conjugated anti-GPIX Ig derivative (Emfret Analytics,
#M051-1) and treated with rmSema7a or IgG2A Fc for 5 min at 37 °C prior to
perfusion. In the case of GPIb-blocking antibody treatment, 100 µg/mouse p0p/B
Fab38 was injected intravenously 20 min before blood was taken for the experiment.
A more detailed description of the flow chamber methods is given in Deppermann
et al. 39. In further experiments, blood of functional GPIb (GPIb-IL4-tg) animals
was used. For further information please see Supplementary material.
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Flow-cytometric analysis. For flow-cytometric analysis, the following antibodies
were used and prepared freshly 1:100 before each experiment: rat anti-mouse Ly6G
labeled with BV421 (Biolegend, #127628), rat anti-mouse CD42b-FITC (Emfret,
#M040-1), rat anti-mouse CD62P labeled Alexa Fluor 647 (BD Pharmingen,
#563674), rat anti-mouse-activated GPIIb/IIIa-PE (Emfret, clone JON/A, #M023-
2). For further information please see Supplementary material.
Gating strategy. After staining, sample acquisition focused granulocytes by their
granularity and surface expression of lymphocyte antigen 6 complex, locus G (Ly-
6G), noted as SSC/Ly-6G+. The presence of platelet surface marker CD42b on the
surface of SSC/Ly-6G+ events distinguished platelet–neutrophil complexes SSC/Ly-
6G+/CD42b+ (PNCs) from free circulating PMNs SSC/Ly-6G+/CD42b−. These
two populations were tested for their display of surface transmembrane glycopro-
teins P-selectin (CD62P) and activated GPIIb/IIIa (clone JON/A). This gating
strategy was adopted to analyze peripheral granulocytes in whole blood as depicted
in Supplementary Fig. 5a, or to focus cardiac muscle AAR granulocytes as shown in
Supplementary Fig. 5b.
SEMA7A cleavage from erythrocytes. Erythrocytes were separated from human
blood samples using MACS beads (MicroBeads Kit, Milenyi Biotec, Germany).
Cells were quantified in a Neubauer chamber. 8 × 108 erythrocytes were employed
per sample. Shear stress was induced by drawing and pushing the erythrocytes
through a 27 gauge needle. For hypoxia exposure cells were placed in hypoxic PBS-
medium exposed to hypoxia (8% O2) in a Invivo2 400 hypoxia workstation (Ruskin
Technology Ltd; Leeds). At the end of each experiment samples were centrifuged
150×g for 10 min at RT and SEMA7A concentration was measured in the super-
natant using the ELISA Kit SEB448Hu.
Intravital microscopy. For a detailed description see Supplementary Video 1.
Data analysis. All data analysis was done in collaboration with the Institute of
Clinical Epidemiology and Applied Biometry of the University Tübingen. Data are
usually presented as bar graphs using mean ± SD. Normal distribution was checked
using skewness. Raw data are accessible in this publication’s data repository.
Because the testing for normality may easily lead to statistically none-significant yet
meaningless results when sample sizes are small, as was the case throughout this
study, we also performed a visual inspection of the data distributions using his-
tograms and tried log-transformation of data to conform to normality, whenever
this inspection revealed skewed distributions. For log-transformed data, tests were
performed on the log values; data are displayed on a logarithmic scale, showing
geometric means and their 95% confidence intervals. Altogether, statistical testing
was performed using Student’s t-tests when comparing two groups; for comparison
of multiple groups, we performed one-way analyses of variance followed by
Dunnett’s tests. For Supplementary Fig. 2: The SEMA7A% on human erythrocytes
and age as input variables was analyzed by linear regression analysis and displayed
pointwise with 95% confidence bands using healthy humans as donors and age as
input variables. For all performed comparisons p-value are displayed and p-values
< 0.05 were considered statistically significant, displayed as p < 0.05 (*); p < 0.01
(**) and p < 0.001 (***).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying main and supplementary figures are provided as a source
datafile. The datasets generated during and/or analyzed during the current study are
available from the corresponding author on reasonable request.
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